Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
DAZAP1 maintains gastric cancer stemness by inducing mitophagy
Peiling Zhang, Wei Wang, Hong Xiang, Yun Zhou, Qian Peng, Guolong Liu, Zhi-Xiang Xu, Lin Lu
Peiling Zhang, Wei Wang, Hong Xiang, Yun Zhou, Qian Peng, Guolong Liu, Zhi-Xiang Xu, Lin Lu
View: Text | PDF
Research Article Cell biology Oncology Stem cells

DAZAP1 maintains gastric cancer stemness by inducing mitophagy

  • Text
  • PDF
Abstract

Stem cells play a pivotal role in the malignant behavior of gastric cancer (GC), complicating its treatment and prognosis. However, the regulatory mechanisms of GC stem cells (GCSCs) remain poorly understood. DAZ-associated protein 1 (DAZAP1), a splicing regulator linked to various malignancies, has an unclear role in GC. This study investigated DAZAP1’s impact on GC stemness and its mechanisms. DAZAP1 promoted tumor progression in GCSCs, as shown by sphere formation assays and stemness marker analysis. Functional enrichment analysis suggested that DAZAP1 enhanced tumor stemness by promoting oxidative phosphorylation (OXPHOS), which was validated through Seahorse assays and measurements of mitochondrial potential. Transmission electron microscopy and immunofluorescence analyses demonstrated that DAZAP1 promoted mitophagy. RNA immunoprecipitation and PCR analysis revealed that DAZAP1 regulated the splicing and expression of the mitophagy-related gene ULK1 through nonsense-mediated mRNA decay. Rescue experiments showed that overexpression of ULK1 reversed the suppression of GC stemness and OXPHOS levels induced by DAZAP1 silencing. Our findings indicate that DAZAP1 reduces ULK1 decay, thereby activating mitophagy and enhancing OXPHOS to fulfill the metabolic demands of cancer stem cells. These findings highlight the therapeutic potential of DAZAP1 as a target for treating GC.

Authors

Peiling Zhang, Wei Wang, Hong Xiang, Yun Zhou, Qian Peng, Guolong Liu, Zhi-Xiang Xu, Lin Lu

×

Figure 3

The impact of DAZAP1 on malignant phenotypes in GC.

Options: View larger image (or click on image) Download as PowerPoint
The impact of DAZAP1 on malignant phenotypes in GC.
(A) DAZAP1 knockdown...
(A) DAZAP1 knockdown in AGS and NCI-N87 cells reduced its expression, while overexpression in HGC27 cells elevated DAZAP1 levels. EV, empty vector. (B) CCK8 assays demonstrated decreased cell viability with DAZAP1 knockdown and increased cell proliferation with its overexpression. (C) EdU assays confirmed that DAZAP1 enhances cell proliferation. (D) Wound healing assays demonstrated that DAZAP1 knockdown reduces cell motility, while DAZAP1 overexpression increases it. (E) Transwell assays showed that DAZAP1 knockdown significantly inhibited, while DAZAP1 overexpression enhanced, the migration and invasiveness of GC cells. (F–H) In vivo tumor formation assays with NCI-N87 cells revealed that DAZAP1 knockdown inhibited tumor growth rate and tumor weight (n = 5/group). Data are presented as mean ± SD. Statistical analysis was by 2-way ANOVA followed by Tukey’s HSD post hoc test for multiple comparisons (B and G), unpaired Student’s t test for comparisons between 2 groups and 1-way ANOVA followed by Tukey’s HSD post hoc test for comparisons among 3 groups (C–E), or 1-way ANOVA followed by Tukey’s HSD post hoc test (H). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts